Biogen submits MS drug candidate Plegridy for FDA approval

05/22/2013 | American City Business Journals

Biogen Idec has filed a biologics license application with the FDA for approval to use its interferon-based drug Plegridy as a treatment for relapsing forms of multiple sclerosis. The application was based on data from a late-stage trial indicating that Plegridy significantly reduced disease activity. Biogen also plans a European application within weeks.

View Full Article in:

American City Business Journals

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Director, Quality Regulatory Affairs
Cardinal Health
Chicago, IL
Regional Director, Southeastern Region - State Affairs
America's Heatlh Insurance Plans (AHIP)
Washington, DC
Regional Director, Southeastern Region - State Affairs
America's Heatlh Insurance Plans (AHIP)
Washington, DC